Jade Biosciences, Inc. Payments to Acquire Short-term Investments
Jade Biosciences, Inc. (JBIO) reported Payments to Acquire Short-term Investments of $19.68 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2025-04-25
- Jade Biosciences, Inc. payments to acquire short-term investments for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Jade Biosciences, Inc. payments to acquire short-term investments for the quarter ending 2024-09-30 was $4.93M, a 89.69% decline year-over-year.
- Jade Biosciences, Inc. payments to acquire short-term investments for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Jade Biosciences, Inc. payments to acquire short-term investments for the quarter ending 2024-03-31 was $14.75M, a 5.50% decline year-over-year.
- Jade Biosciences, Inc. payments to acquire short-term investments for fiscal 2024 was $19.68M, a 84.12% decline from fiscal 2023.
- Jade Biosciences, Inc. payments to acquire short-term investments for fiscal 2023 was $123.98M, a 16.01% decline from fiscal 2022.
- Jade Biosciences, Inc. payments to acquire short-term investments for fiscal 2022 was $147.62M, a 30.35% increase from fiscal 2021.
- Jade Biosciences, Inc. payments to acquire short-term investments for fiscal 2021 was $113.25M.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $4.93M derived: sum of 2 quarters · filed 2025-03-27 | $4.93M derived: sum of 3 quarters · filed 2025-03-27 | $19.68M 10-K · filed 2025-03-27 |
| 2024-09-30 | $4.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $4.93M derived: sum of 2 quarters · filed 2024-11-12 | $19.68M 10-Q · filed 2024-11-12 | $47.47M derived: sum of 4 quarters · filed 2025-04-25 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $14.75M 10-Q · filed 2024-08-12 | $42.54M derived: sum of 3 quarters · filed 2025-04-25 | $90.39M derived: sum of 4 quarters · filed 2025-04-25 |
| 2024-03-31 | $14.75M 10-Q · filed 2025-04-25 | $42.54M derived: sum of 2 quarters · filed 2025-04-25 | $90.39M derived: sum of 3 quarters · filed 2025-04-25 | $123.12M derived: sum of 4 quarters · filed 2025-04-25 |
| 2023-12-31 | $27.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $75.64M derived: sum of 2 quarters · filed 2025-03-27 | $108.37M derived: sum of 3 quarters · filed 2025-03-27 | $123.98M 10-K · filed 2025-03-27 |
| 2023-09-30 | $47.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $80.58M derived: sum of 2 quarters · filed 2024-11-12 | $96.19M 10-Q · filed 2024-11-12 | $146.45M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $32.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $48.35M 10-Q · filed 2024-08-12 | $98.61M derived: sum of 3 quarters · filed 2024-08-12 | $124.18M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $15.61M 10-Q · filed 2024-05-13 | $65.87M derived: sum of 2 quarters · filed 2024-05-13 | $91.44M derived: sum of 3 quarters · filed 2024-05-13 | $130.34M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $50.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $75.83M derived: sum of 2 quarters · filed 2024-03-25 | $114.73M derived: sum of 3 quarters · filed 2024-03-25 | $147.62M 10-K · filed 2024-03-25 |
| 2022-09-30 | $25.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $64.47M derived: sum of 2 quarters · filed 2023-11-13 | $97.36M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $38.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $71.79M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $32.89M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $113.25M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |